Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cubist Pharmaceuticals' antibiotic Cubicin has received approvals for S. aureus bacteremia in both South Korea and Taiwan, according to the company.
Subscribe to our email newsletter
The recent approval in South Korea includes both complicated skin and skin structure infections (cSSSI) and right-sided infective endocarditis (SAB/RIE). Cubicin was previously approved in Taiwan (in November of 2006) for cSSSI caused by Gram positive bacteria.
US-based Cubist said that the approvals were received by the company’s marketing partners, Kuhnil Pharmaceutical Corp for South Korea and TTY BioPharm Company for Taiwan.